ArticleFrontiers in immunology2026
A 12-gene immune signature predicts prognosis and identifies KRT6B as a therapeutic target in lung adenocarcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A m6A/m1A/m5C-related eight-gene signature predicts prognosis and correlates with immune microenvironment in pediatric acute myeloid leukemia.Translational pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) exhibits high mortality and heterogeneity. While immune-related signatures show prognostic potential, robust models validated through both computational screening and experimental methods are lacking. Methods: Transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) database and three Gene Expression Omnibus (GEO) cohorts (GSE3141, GSE30219, and GSE50081) were analyzed. A 12-gene immune-related prognostic signature was constructed using LASSO Cox regression. The model was subsequently validated using three independent external cohorts. Its prognostic performance was comprehensively assessed using time-dependent receiver operating characteristic (ROC) curves. Functional enrichment analyses (GO, KEGG, and GSEA), tumor microenvironment (TME) profiling (via CIBERSORT and ESTIMATE algorithms), and drug sensitivity analyses were conducted. Protein-protein interaction (PPI) network analysis identified KRT6B as a central hub gene. KRT6B expression and its functional role were further validated through tissue microarray immunohistochemistry (IHC), as well as Results: We developed a prognostic model for LUAD based on 12 immune-related genes and derived a risk score via LASSO regression. High-risk patients exhibited significantly worse overall survival compared to low-risk patients in both the training set (TCGA) and the three independent validation cohorts (GSE3141, GSE30219, and GSE50081) (all P < 0.05). Time-dependent ROC analysis confirmed the model's predictive accuracy for 1-, 2-, and 3-year survival (AUC: 0.624-0.788). A nomogram incorporating the risk score and key clinical indicators further enhanced prognostic performance (AUC: 0.753 to 0.763). PPI network analysis pinpointed KRT6B as a core hub gene within the signature. Subsequent experimental validation confirmed the overexpression of KRT6B in LUAD tumor cells and demonstrated its tumor-promoting functions both Conclusion: We established and validated an immune-related gene signature for prognostic prediction and identified KRT6B as a promising prognostic biomarker and potential therapeutic target in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.